Efficacy of Standard-Dose Omalizumab Against Chronic Urticaria: A Real-World Study

IF 3.7 4区医学 Q1 DERMATOLOGY

Dermatologic Therapy Pub Date : 2025-06-20 DOI:10.1155/dth/8754260

Zijing Xiao, Duoqin Wang, Yanyun Shen, Yixin Shao, Lisi Peng, Taiyu Jin, Yiqi Zhu, Hui Tang

{"title":"Efficacy of Standard-Dose Omalizumab Against Chronic Urticaria: A Real-World Study","authors":"Zijing Xiao, Duoqin Wang, Yanyun Shen, Yixin Shao, Lisi Peng, Taiyu Jin, Yiqi Zhu, Hui Tang","doi":"10.1155/dth/8754260","DOIUrl":null,"url":null,"abstract":"<div>\n Background: Omalizumab has been recommended for the treatment of CU. Meanwhile, real-world data are available on the efficacy and safety of omalizumab in patients with CSU, but there is a relative paucity of data on the use of the drug in the treatment of CIndU and CSU combined with CIndU.\n Objective: To evaluate the efficacy and safety of omalizumab in Chinese patients with CSU, CholU, SDerm, or both, who had an inadequate response to H1-antihistamine treatment.\n Methods: This was an observational, retrospective chart review of patients with CU initiating omalizumab treatment.\n Results: In total, 78.4% (n = 80/102) of patients showed a response to omalizumab at the end of the study period, and 36.3% (n = 37/102) showed a complete response. Among patients with different subtypes, 84.8% (n = 38/45) of CSU, 37.5% (n = 3/8) of CholU, 50% (n = 1/2) of SDerm and 80.9% (n = 38/47) of CSU + SDerm comorbidity subgroup patients showed a response. The mean of tIgE levels of responders were significantly higher than nonresponders (649.48 ± 814.69 vs. 264.27 ± 262.49 ng/mL, p = 0.004). Patients with isolated CSU exhibited significantly lower relapse rates compared to the CSU + SDerm comorbidity subgroup (42.9% vs. 57.1%, p = 0.042). In total, 12 patients reinitiated omalizumab treatment after a relapse and all of them showed an early response. The mean response time was 1.33 ± 0.65 months. The response mode was similar with their first treatment.\n Conclusion: Omalizumab is effective in difficult-to-treat patients with CSU and CSU + SDerm comorbidity subgroup, but the response rates in patients with isolated CholU or SDerm are unsatisfactory. The mean of tIgE levels of responders were significantly higher than nonresponders at baseline. Patients in the CSU + SDerm comorbidity subgroup demonstrate an elevated risk of relapse. These findings support omalizumab’s role in refractory CSU and comorbid CSU + SDerm, but highlight unmet needs in isolated CIndU subtypes.\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8754260","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/8754260","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Omalizumab has been recommended for the treatment of CU. Meanwhile, real-world data are available on the efficacy and safety of omalizumab in patients with CSU, but there is a relative paucity of data on the use of the drug in the treatment of CIndU and CSU combined with CIndU.

Objective: To evaluate the efficacy and safety of omalizumab in Chinese patients with CSU, CholU, SDerm, or both, who had an inadequate response to H1-antihistamine treatment.

Methods: This was an observational, retrospective chart review of patients with CU initiating omalizumab treatment.

Results: In total, 78.4% (n = 80/102) of patients showed a response to omalizumab at the end of the study period, and 36.3% (n = 37/102) showed a complete response. Among patients with different subtypes, 84.8% (n = 38/45) of CSU, 37.5% (n = 3/8) of CholU, 50% (n = 1/2) of SDerm and 80.9% (n = 38/47) of CSU + SDerm comorbidity subgroup patients showed a response. The mean of tIgE levels of responders were significantly higher than nonresponders (649.48 ± 814.69 vs. 264.27 ± 262.49 ng/mL, p = 0.004). Patients with isolated CSU exhibited significantly lower relapse rates compared to the CSU + SDerm comorbidity subgroup (42.9% vs. 57.1%, p = 0.042). In total, 12 patients reinitiated omalizumab treatment after a relapse and all of them showed an early response. The mean response time was 1.33 ± 0.65 months. The response mode was similar with their first treatment.

Conclusion: Omalizumab is effective in difficult-to-treat patients with CSU and CSU + SDerm comorbidity subgroup, but the response rates in patients with isolated CholU or SDerm are unsatisfactory. The mean of tIgE levels of responders were significantly higher than nonresponders at baseline. Patients in the CSU + SDerm comorbidity subgroup demonstrate an elevated risk of relapse. These findings support omalizumab’s role in refractory CSU and comorbid CSU + SDerm, but highlight unmet needs in isolated CIndU subtypes.

查看原文本刊更多论文

标准剂量Omalizumab治疗慢性荨麻疹的疗效：一项现实世界研究

背景：Omalizumab已被推荐用于治疗CU。同时，关于omalizumab在CSU患者中的疗效和安全性的真实数据是可获得的，但该药物在cdu和CSU联合cdu治疗中的使用数据相对缺乏。目的：评价omalizumab在中国对h -抗组胺治疗反应不足的CSU、CholU、SDerm或两者同时存在的患者中的疗效和安全性。方法：这是一项观察性、回顾性的图表回顾，回顾了开始奥玛珠单抗治疗的CU患者。结果：在研究期结束时，78.4% （n = 80/102）的患者对omalizumab有反应，36.3% （n = 37/102）的患者完全缓解。不同亚型患者中，84.8% （n = 38/45）的CSU、37.5% （n = 3/8）的CholU、50% （n = 1/2）的SDerm和80.9% （n = 38/47）的CSU + SDerm共病亚组患者出现缓解。应答者的tIgE均值显著高于无应答者（649.48±814.69∶264.27±262.49 ng/mL, p = 0.004）。孤立性CSU患者的复发率明显低于CSU + SDerm合并症亚组（42.9% vs. 57.1%, p = 0.042）。总共有12名患者在复发后重新开始使用omalizumab治疗，并且所有患者都显示出早期反应。平均反应时间为1.33±0.65个月。反应模式与第一次治疗相似。结论：Omalizumab对难以治疗的CSU和CSU + SDerm合并症患者有效，但对孤立性CholU或SDerm患者的有效率不理想。应答者的平均tIgE水平在基线时显著高于无应答者。CSU + SDerm合并症亚组患者复发风险升高。这些发现支持omalizumab在难治性CSU和共病CSU + SDerm中的作用，但突出了孤立CIndU亚型未满足的需求。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.